Stephens Maintains Hologic(HOLX.US) With Buy Rating, Cuts Target Price to $70
Hologic Analyst Ratings
Stephens Adjusts Hologic Price Target to $70 From $77, Maintains Overweight Rating
Morgan Stanley Maintains Hologic(HOLX.US) With Hold Rating, Cuts Target Price to $65
Mizuho Securities Maintains Hologic(HOLX.US) With Buy Rating, Cuts Target Price to $65
Morgan Stanley Cuts Price Target on Hologic to $65 From $77, Keeps Equalweight Rating
Hologic's Financial Outlook: Hold Rating Amid Revenue Decline and Tariff Challenges
A Quick Look at Today's Ratings for Hologic(HOLX.US), With a Forecast Between $65 to $71
RBC Capital Maintains Sector Perform on Hologic, Lowers Price Target to $70
Raymond James Adjusts Hologic Price Target to $71 From $90
Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC), Envista Holdings (NVST) and Hologic (HOLX)
UBS Adjusts Price Target on Hologic to $65 From $80, Maintains Neutral Rating
Hologic Analyst Ratings
Hologic's Mixed Q2 Performance and Revised Earnings Guidance Lead to Hold Rating
Leerink Partners Adjusts Price Target on Hologic to $65 From $75, Maintains Market Perform Rating
Mizuho Securities Maintains Hologic(HOLX.US) With Buy Rating, Cuts Target Price to $75
BofA Securities Maintains Hologic(HOLX.US) With Hold Rating, Cuts Target Price to $70
RBC Capital Maintains Hologic(HOLX.US) With Hold Rating, Cuts Target Price to $75
Evercore ISI Adjusts Price Target on Hologic to $65 From $73, Maintains In Line Rating
Leerink Partners Sticks to Their Hold Rating for Hologic (HOLX)